Researchers discover a mechanism that can increase survival in patients with advanced prostate cancer

Researchers from the IGTP, ICO and IDIBELL have observed that advanced prostate cancer cells that have become resistant to standard treatment have an Achilles heel that can be attacked with a combination of chemotherapies .

Validation of  this cellular mechanism would permit identification  of patients who have developed resistance to standard treatments and the implementation of more personalized medicine for prostate cancer.

Funding for a project focussed on the response to immunotherapy for the treatment of colorectal cancer

This year the Fundación Mutua Madrileña has allocated 2.3 million euros for financing medical research in Spain. Four of the 21 clinical studies benefiting are projects being carried out in Catalan research centres, which will receive a total of 540,000 euros. One of these is being led by the Germans Trias I Pujol Research Institute (IGTP) and coordinated between four groups of the Programme for Predictive and Personalized Medicine of Cancer (IGTP-PMPPC).

A new study shows that increasing the number of cycles with temozolomide for glioblastoma patients brings no additional benefits and increases the toxicity of the treatment

The trial, the results of which have been published in been published in the journal "Neuro Oncology", was led by the researcher and medical oncologist Carme Balaña and included a large group of professionals from the ICO.